At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
mometasone furoate nasal spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex?
In Brief
A clinical study evaluating mometasone furoate nasal spray and placebo for Seasonal Allergic Rhinitis. Completed, enrolled 40 participants across 1 site.
Detailed Summary
We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% response rate in prior studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
CollaboratorsSchering-Plough
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartApr 2008
Primary CompletionJul 2008
Study CompletionJul 2010
TodayJul 2026
First PostedFeb 20, 2008
Enrollment StartApr 1, 2008
Primary CompletionJul 1, 2008
Study CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.4 years ago
Interventions
mometasone furoate nasal spraydrug
2 puffs in each nostril once a day for 2 weeks
placebodrug
2 puffs in each nostril once a day for 2 weeks